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References that met the Institute of Medicine definition of a guideline were included. Guidelines 170"
were excluded if they (1) did not contain recommendations involving the healthy adult population, 171"
(2) were entirely focused on early detection of CVD, (3) were not produced on behalf of a 172"
professional organization, or (4) were not applicable to Western countries. In addition, only 173"
guidelines produced or updated as of May 2009 were eligible for inclusion to avoid overlap with 174"
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Abbreviations: AGREE2, Appraisal of Guidelines Research and Evaluation II; EI, editorial; 
independence declared; FIP, funding by industrial partner reported; SCI, statement about conflicts 
of interest of group members present; UK, United Kingdom 
*Relationship with industry is reported by any group member;  
† A group member is reported recused when a relevant area is under discussion;  
‡ Conflicts of interest only available on request; 




Table 1. Characteristics of 21 Guidelines       
Guideline by Medical 
Condition, year 









  Total Cardiovascular risk     NICE (14), 2014 National Institute for Health and Clinical Excellence UK 86 EI,SCI*† ESC (15), 2012 European Society of Cardiology Europe 86 SCI* NVDPA (16), 2012 National Vascular Disease Prevention Alliance Australia 85 EI,SCI† ACC/AHA (17-19), 2013 American College of Cardiology United States 83 SCI*† CDC (20), 2011 Centres for Disease Control and Prevention United States 65 EI,SCI*† BCS (21), 2014 British Cardiovascular Society UK 45 SCI* NZGG (22), 2012 New Zealand Guidelines Group New Zealand 20 EI,SCI‡          Dyslipidemia     ESC (23), 2011 European Society of Cardiology Europe 72 SCI* ACCE (24), 2012 American Association of Clinical Endocrinologists United States 64 SCI* CCS (25), 2013 Canadian Cardiovascular society Canada 42 EI,SCI*          Dysglycemia     ADS/DAGDC (26), 2009 Australian Diabetes Society Australia 87 SCI‡ CDA (27), 2013 Canadian Diabetes Association Canada 83 EI,FIP,SCI*† ADA (28), 2014 American Diabetes Association United States 68 SCI* USPSTF (29), 2015 U.S. Preventative Services Task Force United States 76 EI, SCI NICE (30), 2012 National Institute for Health and Clinical Excellence UK 73   CTFPHC (31), 2012 Canadian Task Force on Preventive Health Care Canada 68 EI,SCI* ESC (32), 2013 European Society of Cardiology Europe 66 SCI* IDF (33), 2012 International Diabetes Federation International 47 FIP, SCI§          Hypertension     CHS (34,35), 2015 Canadian Hypertension Society Canada 90 EI,SCI*† USPSTF (36),2015 U.S. Preventative Services Task Force United States 79 EI, SCI CTFPHC (37), 2013 Canadian Task Force on Preventive Health Care 
 
Canada 78 SCI 
Table 2. Recommendations for Screening in Total CVD Risk in 5 Guidelines 
  ESC NICE NVDPA ACC/ AHA CDC/ AHA Country  Europe UK Australia USA USA Year 2016 2014 2012 2013 2011 
AGREE 2 Score 86% 86% 85% 83% 65% 
Method to evaluate 
evidence 








Methods to formulate 
recommendations 















Performed CEA  






Target Group Men > 40 y, 
Women >50 y 
or post 
menopausal  
Aged 40-74 (NHS Health Check) All adults aged >45 y or Aboriginal & Torres Strait Islanders >35y 
Aged 21 and above Women ≥20 y  
Strategy Opportunistic screening/ case finding Opportunistic screening/ case finding/ record based 
Opportunistic screening/ case finding Opportunistic screening/ case finding NR Strength of recommendation For For For For Not for and not against 




at 10 y 
QRISK2, 
CHD/stroke/TIA 
events at 10 y 
Framingham, 
CHD/stroke 




events at 10 y 
if age 40-79 y 
or lifetime (30 
y) risk for 20-
59 y with 10 y 





at 10 y 
Age ✓1 ✓1 ✓1 ✓1 ✓1 
Sex ✓1 ✓1 ✓1 ✓1 ✓1 
Blood pressure ✓1 ✓1 ✓1 ✓1 ✓1 
TC level ✓1 ✓1 ✓1 ✓1 ✓1 
LDL-C level ✓2 ✓2 ✓2     
HDL-C level ✓1 ✓1 ✓1 ✓1 ✓1 
TC:HDL-C ratio ✓1 ✓1 ✓1 ✓1   
Smoking ✓1 ✓1 ✓1 ✓1 ✓1 
Glucose levels   ✓2 ✓2     
Underlying risk factors           
Overweight/obesity ✓2 ✓1 ✓2   ✓1 
Physical inactivity ✓2   ✓2   ✓1 
Atherogenic diet           
Socioeconomic factors ✓2 ✓1 ✓2     
Family history of 
premature CVD 
✓2 ✓1 ✓2 ✓3 ✓1 
Genetic/racial factors ✓2 ✓1 ✓2 ✓1 ✓1 
Diabetes ✓2 ✓1 ✓1 ✓1 ✓1 
Antihypertensives ✓2 ✓1   ✓1   
Emerging risk factors           
TG levels ✓2 ✓2 ✓2     
Renal function ✓2 ✓1 ✓2   ✓1 
      
Table 2. Recommendations for Screening in Total CVD Risk in 5 Guidelines (continued). 
  ESC NICE NVDPA ACC/ AHA CDC/ AHA 
Heart rate ✓2         
Apo/lipoprotein levels ✓4        
Glucose therapy for 
insulin resistance 
          
Prothrombotic markers ✓4         
C-reactive protein level ✓4     ✓3   
Subclinical 
atherosclerosis 
✓4 (ABI, CAC 
score, carotid 
US for plaque) 
  ✓1 (LVH) ✓3 (ABI, CAC 
score) 
  















Statins 10 y CVD 
mortality ≥10% 
and LDL-C level 
≥70 mg/dL; 10 y 
risk 5%-10% and 
LDL-C level ≥100 
mg/dL; consider 
if 10 y risk <5% 
and LCL-C 
>115mg/dL; 
DM2 or DM1 
and age >40 y 
10 y 
CHD/stroke/TIA 
risk ≥10%; DM2 




DM1; CKD with 
eGFR <60 











40 -75 y with 
10 y 
CHD/stroke 
risk ≥7.5% and 
LDL-C 70-189 
mg/dL; 40-75 





10 y risk 
>20%; DM 
Antihypertensives 10 y CVD 
mortality ≥10% 
and BP ≥140/90 
mmHg; consider 
if 10 y risk 5-
10% and BP 
≥140/90 mmHg; 
DM1 or DM2 
and BP ≥140/85 
mmHg; over 60 
y and systolic BP 
>150mmHg or 
more than 80 y 




NR 5 y FRS ≥ 15%; 
FRS 10-15% and 
BP persistently 
≥ 160/100/ FHx 
CVD, high risk 
ethnicity; 
consider if FRS 




NR BP ≥140/90 
mmHg; 
>130/85 in 
CKD and DM 
Intensive Lifestyle 
Counseling 
10 y CVD 





5 y CHD/stroke 
risk ≥10%. 









      
Table 2. Recommendations for Screening in Total CVD Risk in 5 Guidelines (continued). 
  ESC NICE  NVDPA ACC/ AHA CDC/ AHA 




if 5 y 
CHD/stroke risk 
≥ 15%. Monitor 
risk profile 
every 6-12 




Screening Intervals NR Further risk 
assessment on 
an on going 
basis. 5 yearly 
as per NSF  
Further risk 
assessment 











Abbreviations: ABI, ankle brachial index; ASCVD, atherosclerotic cardiovascular disease; CEA, cost-
effectiveness analysis; CAC, coronary artery calcium; CHD, coronary heart disease; CKD, chronic 
kidney disease; CVD, cardiovascular disease; DM - diabetes mellitus; FHx, family history; HDL-C, 
high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; LVH, left 
ventricular hypertrophy; NHS, National Health Service; NR, not reported; NSF, National Service 
Framework; SCORE, Systematic Coronary Risk Evaluation; TC, total cholesterol; TG, triglyceride; 
TIA, transient ischemic attack; UK, United Kingdom; US, ultrasound; y, years;  
✓1, Formal screening test (included in the prediction model); 
✓2, Additional screening test 
✓3, In selected individuals who are not in 1 of the 4 main statin benefit groups, and for who a 
decision to initiate statin therapy is otherwise unclear, additional factors may be considered to 
inform treatment decision-making.  These factors include; 1. Primary LDL–C ≥160 mg/dL or other 
evidence of genetic hyperlipidemias, 2. First degree relative with premature ASCVD, 3. High-
sensitivity C-reactive protein >2 mg/L, 4. CAC score ≥300 Agatston units or ≥75 percentile for age, 
sex, and ethnicity, 5. Ankle-brachial index <0.9, or 6. Elevated lifetime risk of ASCVD.  
✓4, Novel biomarkers have only limited additional value when added to CVD risk 
assessment with the SCORE algorithm in come limited cases.                 
Appendix Table 1: Website searches of guideline development organizations, including websites 
affiliated with all the guidelines included in our previous publication 
Organization Responsible for 
Guideline Development 
Country  Website Searched 
American Academy of Family 
Physicians (AAFP) 
United States http://www.aafp.org/online/en/home.html 
American Association of Clinical 
Endocrinologists 
United States www.aace.com 
American College of Cardiology United States http://www.acc.org/ 
American College of Physicians United States http://www.acponline.org/ 
American College for 
Preventive Medicine 
United States http://www.acpm.org/ 
American Diabetes Association 
(ADA) 
United States http://www.diabetes.org/ 
American Geriatrics Society 
(AGS) 
United States http://www.americangeriatrics.org/ 
American Heart Association 
(AHA) 
United States http://www.americanheart.org/ 
American Medical Association 
(AMA) 
United States http://www.ama-assn.org/ 
American Stroke Association United States http://www.strokeassociation.org/ 
Australian Diabetes Society 
(ADS) 
Australia https://www.diabetessociety.com.au/ 




British Cardiac Society (BCS) United Kingdom http://www.bcs.com/pages/default.asp 
British Hypertension Society 
(BHS) 
United Kingdom http://www.bhsoc.org/default.stm 
Canadian Diabetes Association Canada http://guidelines.diabetes.ca/ 
Canadian Hypertension Society 
(CHS) 
Canada http://www.hypertension.ca/ 
Canadian Task Force on 
Preventive Health Care 
(CTFPHC) 
Canada http://canadiantaskforce.ca/ 
Cardiac Society of Australia and 
New Zealand (CSANZ) 
Australia http://www.csanz.edu.au/ 
Centers for Disease Control and 
Prevention (CDC)/ AHA 
United States http://www.cdc.gov/ 
Department of Health (DOH) United Kingdom http://www.dh.gov.uk/en/index.htm 




International Society of 
Hypertension 
International http://www.ish-world.com/ 
National Health and Medical 
Research Council (NHMRC) 
Australia http://www.nhmrc.gov.au/index.htm 
National Heart Foundation Australia http://www.heartfoundation.org.au/index.htm 
National Heart Lung and Blood 
Institute 
United States http://www.nhlbi.nih.gov/guidelines/index.htm 
National Institute for Health 
and Clinical Excellence (NICE) 
United Kingdom http://www.nice.org.uk/ 
New Zealand Guidelines Group New Zealand http://www.nzgg.org.nz/index.cfm? 
Royal College of General 
Practitioners (RCGP) 
United Kingdom http://www.rcgp.org.uk/default.aspx 
   
   
   
Appendix Table 1: Website searches of guideline development organizations, 
including websites affiliated with all the guidelines included in our previous 
publication (continued) 
Organization Responsible for 
Guideline Development 
Country  Website Searched 
Scottish Intercollegiate 
Guidelines Network (SIGN) 
United Kingdom http://www.sign.ac.uk/ 
   
U.S. Preventive Services Task 
Force (USPSTF) 
United States http://www.ahrq.gov/clinic/uspstfix.htm 
World Heart Federation International http://www.world-heart-federation.org/ 
World Health Organisation 
(WHO) 
International http://www.who.int/en/ 
World Hypertension League International http://www.worldhypertensionleague.org/Pag
es/Home.aspx 
International Diabetes 
Federation European Region 
International http://diabetespreventionforum.org/index.php
/projects/6-image-project                                    
Appendix Table 2. Recommendations for Screening for Dysglycemia in 6 Guidelines 
  DAGDC CDA ADA USPSTF NICE PH38 CTFPHC ESC 
Country Australia Canada USA USA UK Canada Europe 
Year 2009 2013 2016 2015 2012 2012 2013 
AGREE 2 Score 87% 83% 82% 76% 73% 68% 66% 
Method to evaluate 
evidence 
Systematic review  Systematic review Systematic review Systematic review Systematic review Systematic review  Systematic review  
Methods to formulate 
recommendations 
Formal consensus Formal consensus Formal consensus Consensus Consensus Formal consensus Formal consensus 
Consideration of costs Review of CEA 
studies 
Review of CEA 
studies 
Review of CEA 
studies 
Review of CEA 
studies  





Performed CEA  
NR 





All adults aged 
≥40y or high risk 
groups using risk 
calculator 
All adults over 45 y or 
all Adults with BMI 
≥25 (or ≥23 kg/m2 in 
Asian Americans) and 
1 additional DM risk 
factor 
Adults aged 40-70 
y with BMI ≥25  
> 40 y; 25-39 y 
South Asian, 
Chinese, Black 




FINDRISC ≥ 15/26 


























For For For For - moderate 





For - only in high 
risk groups 
For - only in high 
risk groups 








       
        
Appendix Table 2. Recommendations for Screening for Dysglycemia in 6 Guidelines (continued) 
  DAGDC CDA ADA USPSTF NICE PH38 CTFPHC ESC4 










NR Diabetes UK score  FINDRISC, 10 y DM 
risk or other 
validated risk score 
(e.g. CANRISK) 
FINDRISC, 10 y DM 
risk 
Age ✓1 ✓1 ✓1 ✓1 ✓1 ✓1 ✓1 
Sex ✓1     ✓1 ✓1 ✓1 ✓1 
Blood pressure     ✓1       ✓1 
TC level               
HDL-C level ✓2 ✓1 ✓1         
TC:HDL-C ratio       ✓1       
Smoking ✓1   ✓1 ✓1       
Glucose levels ✓2 ✓1 (or HBA1C) ✓1   ✓2 (or HBA1C) ✓2 (or HBA1C)   
Underlying risk factors               
Overweight/obesity ✓1 ✓1 ✓1 ✓1 ✓1 ✓1 ✓1 
Physical inactivity ✓1   ✓1 ✓1   ✓1 ✓1 
Atherogenetic diet           ✓1   
Family history of 
premature CVD   ✓1 ✓1         
Genetic/racial factors ✓1 ✓1 ✓1 ✓1 ✓1 ✓1   
Antihypertensive 
Therapy ✓1 ✓1 ✓1 ✓1   ✓1 ✓1 
Emerging risk factors               
TG levels ✓2 ✓1 ✓1         
Renal function               
Thresholds              
Aspirin NR Not routinely 
recommended. 
May be used in 
presence of other 
CVD risk factors 
Consider if DM with 
10 y ASCVD risk 
≥10%. Consider 
aspirin in women ≥50 
y. Clinical judgment 
required for 
antiplatelet use if  
<50 y with multiple 
risk factors and 10 y 
ASCVD risk 5-10% 
Not 
recommended  NR NR Consider in high risk DM patients on an individual basis 
        
Appendix Table 2. Recommendations for Screening for Dysglycemia in 6 Guidelines (continued) 
  DAGDC CDA ADA USPSTF NICE PH38 CTFPHC ESC4 
Statins NR If found diabetic 
in men > 40 y; < 
40 y with 
microvascular 
complications, 
diabetes for >15 y 
and >30 y old 
Consider moderate 
or high intensity 
statin if DM and 40-
75 y, DM and > 75 y 
or if DM and < 40 y 
with one or more 
other ASCVD risk 
factors (family history 
of premature ASCVD, 
hypertension, 
smoking, overweight 
or obese, LDL 
>100mg/dL; High 
intensity statin if 40-
75 y with additional 
ASCVD risk factor. 
Moderate to high 
intensity statin if >75 
y and additional 
ASCVD risk factors  
NR NR NR Very high risk; Severe 
renal disease, 1 other 
CVD risk factor or 
target organ damage 
and LDL-C >70mg/dL; 
T2DM and LDL-C 
>100mg/dL 
Antihypertensives NR If found diabetic 
and BP>130/80 
mmHg DM and BP >140/90mmHg NR NR NR DM and BP >140/85mmHg 
Intensive Lifestyle 
Counseling IFG; IGT IFG; IGT IGT or IFG or A1C 5.7-6.4 mmol/L For those with abnormal blood 
glucose (IGT, IFG 
or diabetes); BMI 
>25 kg/ m2 and 
additional CVD 
risk factors; BMI ≥ 
30 kg/ m2 
High risk and 
IFG/HBA1C 42 -47 NR High risk for developing DM  
High-risk Monitoring Yearly if IFG/ IGT Yearly if IFG/ IGT Annual screening if 
IGT or IFG or A1C 5.7-
6.4 mmol/L NR Every year if high risk and IFG or HBA1C 42 -47 
mmol/mol 
Annual screening if 
very high risk (e.g. 
FIND RISK >20) Depending on clinical context 
        
        
Appendix Table 2. Recommendations for Screening for Dysglycemia in 6 Guidelines (continued). 
  DAGDC CDA ADA USPSTF NICE PH38 CTFPHC ESC4 
Screening Intervals 3 y; annual if 
IFG/IGT 3 y; annual if IFG/IGT 3 y if normal; 6-12 postpartum if GDM 
then every 3 years if 
normal  
3 y if normal 
glucose levels    At least 5 y starting with risk assessment tool 
for low risk; 3 
yearly for those at 
moderate risk of 
diabetes 
3- 5 y NR 
Appendix Table 3. Recommendations for Screening for Dyslipidemia in 2 Guidelines 
 ESC AACE 
Country Europe USA 
 Year 2011 2012 
AGREE 2 Score 72% 64% 
Method to evaluate 
evidence 
Systematic review  Review of published systematic reviews 
and RCTs; literature identified by panel 
members 
Methods to formulate 
recommendations 
Formal consensus Formal consensus 
Consideration of costs NR Review of CEA studies 
Target Group DM, hypertension, smokers, BMI ≥ 30, FHx 
premature CVD, FHx of familial 
hypercholesterolemias, CKD, Chronic 
inflammatory conditions, Men > 40 y, 
Women >50 y or post menopausal 
Aged ≥ 20 y 




Major risk factors 
prediction model SCORE, general ASCVD mortality at 10 y 
Framingham/ Reynolds Risk Score, 
CHD/stroke at 10 y 
Age ✓1 ✓1 
Sex ✓1 ✓1 
Blood pressure ✓1 ✓1 
TC level ✓1 ✓1 
LDL-C level ✓1 ✓1 
HDL-C level ✓1 ✓1 
TC:HDL-C ratio ✓1 ✓1 
Smoking ✓1 ✓1 
Underlying risk factors     
Family history of 
premature CVD 
  ✓1 
Diabetes   ✓1 
Emerging risk factors     





Glucose therapy for 
insulin resistance 
 ✓1  
Prothrombotic markers   ✓3 
C-reactive protein level   ✓3 
Thresholds     
Aspirin NR NR 
Statins 10 y CVD mortality risk ≥10% and LDL-C 
level ≥70 mg/dL; 10 y CVD mortality 5%-9% 
and LDL-C level ≥100 mg/dL;        (Type 1 DM 
or Type 2 DM) and LDL-C level ≥70 mg/dL; 
very high CV risk (Type 2 DM, Type 1 DM 
with target organ damage, CKD) 
Treat to target based on personalized risk 
LDL-C to < 100mg/dL if average or 
elevated LDL; other parameters based on 
target levels  
Antihypertensives NR NR 
Intensive Lifestyle 
Counseling 
10 y CVD mortality >1% or LDL-C > 
100mg/dL 
10 y risk ≥20% 
High-risk Monitoring NR NR 
Screening Intervals NR Every 5 y if risk aged ≥ 20 y, every 1-2 y if 
aged ≥45 male or aged ≥55 y female 
Abbreviations: ABI, ankle brachial index; ASCVD, atherosclerotic cardiovascular disease; CEA, cost-
effectiveness analysis; CHD, coronary heart disease; CKD, chronic kidney disease; CVD, 
cardiovascular disease; DM - diabetes mellitus; FHx, family history; HDL-C, high density lipoprotein 
cholesterol; LDL-C, low density lipoprotein cholesterol; LVH, left ventricular hypertrophy; NR, not 
reported; RCT, randomized controlled trial; SCORE, Systematic Coronary Risk Evaluation; TC, total 
cholesterol; TG, triglyceride; TIA, transient ischemic attack; y, years;  
✓1, Formal screening test (included in the prediction model); 
✓2, Additional screening test 
✓3, In selected individuals who are not in 1 of the 4 main statin benefit groups, and for who a 
decision to initiate statin therapy is otherwise unclear, additional factors may be considered to 
inform treatment decision-making.  These factors include; 1. Primary LDL–C ≥160 mg/dL or other 
evidence of genetic hyperlipidemias, 2. First degree relative with premature ASCVD, 3. High-
sensitivity C-reactive protein >2 mg/L, 4. CAC score ≥300 Agatston units or ≥75 percentile for age, 
sex, and ethnicity, 5. Ankle-brachial index <0.9, or 6. Elevated lifetime risk of ASCVD.                                         
Appendix Table 4. Recommendations for Screening for Hypertension in 2 Guidelines 
  CHEP USPSTF CTFPHC 
Country Canada USA Canada 
Year  2015 2015 2013 
AGREE 2 Score 90% 79% 78% 
Method to evaluate 
evidence 
Systematic review  Systematic review Systematic review  
Methods to formulate 
recommendations 
Formal consensus Consensus Consensus 
Consideration of costs NR NR NR 
Target Group All adults  ≥ 18 y with increased 
risk of high BP: high-
normal blood pressure 
(130–139/85–89 mm 
Hg), overweight or 
obese, and African 
Americans 
 ≥ 18 y 
Strategy Opportunistic screening at 
'appropriate visits' 
NR Opportunistic screening at 
'appropriate visits'/ case finding 
Strength of 
recommendation 
For For For 
Major risk factors 
prediction model 
SCORE - Canada, general ASCVD 
mortality at 10 y NR NR 
Age ✓1 ✓1 ✓1 
Sex ✓1     
Blood pressure ✓1 ✓1 ✓1 
TC level ✓1     
HDL-C level ✓1     
Smoking ✓1     
Underlying risk factors       
Overweight/obesity ✓1 ✓1   
Physical inactivity ✓1     
Atherogenetic diet ✓1     
Family history of 
premature CVD 
      
Genetic/racial factors   ✓1 ✓1 
Diabetes ✓1     
Emerging risk factors       
Renal function ✓1     
Subclinical 
atherosclerosis 
LVH/ resting ECG   LVH/ resting ECG 
Thresholds       
Aspirin Consider if ≥ 50 y and 
hypertensive 
NR NR 
Statins If 3 or more of - (male/ ≥55 y/ 
smoking/ Type 2 DM/ Total-
C/HDL-C ration ≥ 6/ FHx CVD/ 
LVH/ ECG abnormalities/ 
Microalbuminuria/ PVD 
NR NR 
Antihypertensives If found diabetic and 
BP>130/80mmHg; High-risk for 
diabetes and BP >140/90;Low-
risk and BP >160/100; ≥ 80 y 
and systolic >160 
NR  NR 
Intensive Lifestyle 
Counseling 
In all with hypertension NR NR 
 
 
   
Appendix Table 4. Recommendations for Screening for Hypertension in 2 Guidelines (continued) 
  CHEP USPSTF CTFPHC 
    
High-risk Monitoring Annual if BP high normal (≥ 
130/85) 
Annually if ≥40 y and at 
increased risk for high 
BP  
Annual if BP high normal (≥ 
130/85) 
Screening Intervals NR Annually if ≥40 y and at 
increased risk for high 
BP.  Every 3 to 5 y if 18 
to 39 y with normal BP 
(<130/85 mm Hg) and 
not other risk factors. 
Further risk assessment based 
on clinical judgment 
Abbreviations: ABI, ankle brachial index; ASCVD, atherosclerotic cardiovascular disease; CHD, 
coronary heart disease; CKD, chronic kidney disease; CVD, cardiovascular disease; DM - diabetes 
mellitus; FHx, family history; HDL-C, high density lipoprotein cholesterol; LDL-C, low density 
lipoprotein cholesterol; LVH, left ventricular hypertrophy; NR, not reported; PVD, peripheral 
vascular disease; SCORE, Systematic Coronary Risk Evaluation; TC, total cholesterol; TG, 
triglyceride; TIA, transient ischemic attack; US, ultrasound; y, years;  
✓1, Formal screening test (included in the prediction model);      
!! !! !! !! !! !! !!
!! 3553#Cita(ons#iden(ﬁed# !! !! !! !!
!! 2465!MEDLINE! !! !! !! !!
!! 339!Pubmed!4!Epub!ahead!of!print! !! !! !! !!
!! 721!CINAHL! !! !! !! !!
!! 28!Web!sites! !! !! !! !!
!! !! !! !! !! !! !!
!! !! 255!Duplicates! !! !!
!! !! !! !! !! !! !!
!! 3298#Titles#reviewed# !! !! !! !!
!! !! !! !! !! !! !!
!! !! 3118!Excluded! !! !!
!! !! !! !! !! !! !!
!! 180#Abstracts#reviewed# !! !! !! !!
!! !! !! !! !! !! !!
!! !! 133!Excluded! !!
!! !! 7!Background!Piece! !!
!! !! 5!Not!Applicable!to!Selected!Countries! !!
!! !! 10!Not!AsymptomaOc! !!
!! !! 3!Not!Focused!on!Screening! !!
!! !! 2!Not!NaOonal!or!PannaOonal! !!
!! !! 63!Not!Part!of!a!Guideline! !!
!! !! 14!Not!Relevant! !!
!! !! 29!Not!the!most!Recent! !!
!! !! !! !! !! !! !!
!! 37#Full#text#reviewed# !! !! !! !!
!! !! !! !! !! !! !!
!! !! 26!Excluded! !!
!! !! 4!Not!AsymptomaOc! !!
!! !! 5!Not!Focused!on!Screening! !!
!! !! 5!Not!NaOonal!or!PannaOonal! !!
!! !! 2!Not!Part!of!a!Guideline! !!
!! !! 5!Not!Relevant! !!
!! !! 5!Not!the!most!Recent! !!




!!!!!4!!!AGREE!II!rigor!score!<50%! !! !! !! !!
!! !! !! !! !! !! !!
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